Do analysts recommend GOSS or TLSA?

Gossamer Bio currently has a consensus target price of $3.20, suggesting a potential upside of 1,722.32%. Given Gossamer Bio's stronger consensus rating and higher possible upside, equities research analysts plainly believe Gossamer Bio is more favorable than Tiziana Life Sciences. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Gossamer Bio 2 Sell rating(s) 3 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.22 Tiziana Life Sciences 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has preferable earnings and valuation, GOSS or TLSA?

Tiziana Life Sciences has lower revenue, but higher earnings than Gossamer Bio. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Gossamer Bio $48.47M 0.85 -$170.37M -$0.70 N/A Tiziana Life Sciences N/A N/A -$18.43M N/A N/A

Is GOSS or TLSA more profitable?

Tiziana Life Sciences has a net margin of 0.00% compared to Gossamer Bio's net margin of -235.00%. Company Net Margins Return on Equity Return on Assets Gossamer Bio -235.00% N/A -112.04% Tiziana Life Sciences N/A N/A N/A

Does the media refer more to GOSS or TLSA?

In the previous week, Gossamer Bio had 7 more articles in the media than Tiziana Life Sciences. MarketBeat recorded 10 mentions for Gossamer Bio and 3 mentions for Tiziana Life Sciences. Gossamer Bio's average media sentiment score of 0.20 beat Tiziana Life Sciences' score of 0.00 indicating that Gossamer Bio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Gossamer Bio 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Tiziana Life Sciences 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is GOSS or IMDX more profitable?

Gossamer Bio has a net margin of -235.00% compared to Oncocyte's net margin of -2,955.63%. Company Net Margins Return on Equity Return on Assets Gossamer Bio -235.00% N/A -112.04% Oncocyte -2,955.63% N/A -107.52%

Does the media favor GOSS or IMDX?

In the previous week, Gossamer Bio had 9 more articles in the media than Oncocyte. MarketBeat recorded 10 mentions for Gossamer Bio and 1 mentions for Oncocyte. Gossamer Bio's average media sentiment score of 0.20 beat Oncocyte's score of 0.00 indicating that Gossamer Bio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Gossamer Bio 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Oncocyte 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor GOSS or PMN?

In the previous week, Gossamer Bio had 7 more articles in the media than Promis Neurosciences. MarketBeat recorded 10 mentions for Gossamer Bio and 3 mentions for Promis Neurosciences. Promis Neurosciences' average media sentiment score of 0.34 beat Gossamer Bio's score of 0.20 indicating that Promis Neurosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Gossamer Bio 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Promis Neurosciences 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger earnings & valuation, CBUS or GOSS?

Cibus has higher earnings, but lower revenue than Gossamer Bio. Cibus is trading at a lower price-to-earnings ratio than Gossamer Bio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cibus $3.64M 33.18 -$127.08M -$1.65 N/A Gossamer Bio $48.47M 0.85 -$170.37M -$0.70 N/A

Is CBUS or GOSS more profitable?

Gossamer Bio has a net margin of -235.00% compared to Cibus' net margin of -2,258.89%. Gossamer Bio's return on equity of 0.00% beat Cibus' return on equity. Company Net Margins Return on Equity Return on Assets Cibus -2,258.89% -287.03% -27.99% Gossamer Bio -235.00% N/A -112.04%

Does the media prefer GOSS or HURA?

In the previous week, Gossamer Bio had 7 more articles in the media than TuHURA Biosciences. MarketBeat recorded 10 mentions for Gossamer Bio and 3 mentions for TuHURA Biosciences. TuHURA Biosciences' average media sentiment score of 0.48 beat Gossamer Bio's score of 0.20 indicating that TuHURA Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Gossamer Bio 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral TuHURA Biosciences 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Gossamer Bio (GOSS) Competitors

$0.18 +0.00 (+1.68%)

As of 09/3/2026 04:00 PM Eastern

Compare

GOSS vs. TLSA, IMDX, PMN, CBUS, and HURA

Should you buy Gossamer Bio stock or one of its competitors? Gossamer Bio's main competitors and comparable companies include Tiziana Life Sciences (TLSA), Oncocyte (IMDX), Promis Neurosciences (PMN), Cibus (CBUS), and TuHURA Biosciences (HURA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Gossamer Bio compare to Tiziana Life Sciences?

Gossamer Bio (NASDAQ:GOSS) and Tiziana Life Sciences (NASDAQ:TLSA) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, institutional ownership, media sentiment, valuation, dividends, risk and profitability.

Tiziana Life Sciences has a net margin of 0.00% compared to Gossamer Bio's net margin of -235.00%.

Company	Net Margins	Return on Equity	Return on Assets
Gossamer Bio	-235.00%	N/A	-112.04%
Tiziana Life Sciences	N/A	N/A	N/A

Gossamer Bio currently has a consensus target price of $3.20, suggesting a potential upside of 1,722.32%. Given Gossamer Bio's stronger consensus rating and higher possible upside, equities research analysts plainly believe Gossamer Bio is more favorable than Tiziana Life Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gossamer Bio	2 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.22
Tiziana Life Sciences	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Tiziana Life Sciences has lower revenue, but higher earnings than Gossamer Bio.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gossamer Bio	$48.47M	0.85	-$170.37M	-$0.70	N/A
Tiziana Life Sciences	N/A	N/A	-$18.43M	N/A	N/A

In the previous week, Gossamer Bio had 7 more articles in the media than Tiziana Life Sciences. MarketBeat recorded 10 mentions for Gossamer Bio and 3 mentions for Tiziana Life Sciences. Gossamer Bio's average media sentiment score of 0.20 beat Tiziana Life Sciences' score of 0.00 indicating that Gossamer Bio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Gossamer Bio	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Tiziana Life Sciences	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Gossamer Bio has a beta of 2, indicating that its stock price is 100% more volatile than the broader market. Comparatively, Tiziana Life Sciences has a beta of 0.52, indicating that its stock price is 48% less volatile than the broader market.

81.2% of Gossamer Bio shares are owned by institutional investors. 3.7% of Gossamer Bio shares are owned by insiders. Comparatively, 39.8% of Tiziana Life Sciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Gossamer Bio beats Tiziana Life Sciences on 8 of the 12 factors compared between the two stocks.

How does Gossamer Bio compare to Oncocyte?

Gossamer Bio (NASDAQ:GOSS) and Oncocyte (NASDAQ:IMDX) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their profitability, risk, institutional ownership, media sentiment, earnings, valuation, dividends and analyst recommendations.

Oncocyte has lower revenue, but higher earnings than Gossamer Bio. Oncocyte is trading at a lower price-to-earnings ratio than Gossamer Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gossamer Bio	$48.47M	0.85	-$170.37M	-$0.70	N/A
Oncocyte	$4.05M	33.29	-$50.22M	-$1.49	N/A

Gossamer Bio has a beta of 2, suggesting that its share price is 100% more volatile than the broader market. Comparatively, Oncocyte has a beta of 1.8, suggesting that its share price is 80% more volatile than the broader market.

Gossamer Bio currently has a consensus price target of $3.20, suggesting a potential upside of 1,722.32%. Oncocyte has a consensus price target of $10.50, suggesting a potential upside of 154.85%. Given Gossamer Bio's higher probable upside, equities research analysts plainly believe Gossamer Bio is more favorable than Oncocyte.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gossamer Bio	2 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.22
Oncocyte	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Gossamer Bio has a net margin of -235.00% compared to Oncocyte's net margin of -2,955.63%.

Company	Net Margins	Return on Equity	Return on Assets
Gossamer Bio	-235.00%	N/A	-112.04%
Oncocyte	-2,955.63%	N/A	-107.52%

81.2% of Gossamer Bio shares are held by institutional investors. Comparatively, 55.4% of Oncocyte shares are held by institutional investors. 3.7% of Gossamer Bio shares are held by company insiders. Comparatively, 2.2% of Oncocyte shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

In the previous week, Gossamer Bio had 9 more articles in the media than Oncocyte. MarketBeat recorded 10 mentions for Gossamer Bio and 1 mentions for Oncocyte. Gossamer Bio's average media sentiment score of 0.20 beat Oncocyte's score of 0.00 indicating that Gossamer Bio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Gossamer Bio	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Oncocyte	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Gossamer Bio beats Oncocyte on 11 of the 15 factors compared between the two stocks.

How does Gossamer Bio compare to Promis Neurosciences?

Gossamer Bio (NASDAQ:GOSS) and Promis Neurosciences (NASDAQ:PMN) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, profitability, institutional ownership, valuation, media sentiment, dividends, analyst recommendations and risk.

Gossamer Bio has a beta of 2, meaning that its stock price is 100% more volatile than the broader market. Comparatively, Promis Neurosciences has a beta of -0.24, meaning that its stock price is 124% less volatile than the broader market.

In the previous week, Gossamer Bio had 7 more articles in the media than Promis Neurosciences. MarketBeat recorded 10 mentions for Gossamer Bio and 3 mentions for Promis Neurosciences. Promis Neurosciences' average media sentiment score of 0.34 beat Gossamer Bio's score of 0.20 indicating that Promis Neurosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Gossamer Bio	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Promis Neurosciences	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

81.2% of Gossamer Bio shares are owned by institutional investors. Comparatively, 50.1% of Promis Neurosciences shares are owned by institutional investors. 3.7% of Gossamer Bio shares are owned by insiders. Comparatively, 1.5% of Promis Neurosciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Gossamer Bio presently has a consensus price target of $3.20, suggesting a potential upside of 1,722.32%. Promis Neurosciences has a consensus price target of $34.00, suggesting a potential upside of 163.57%. Given Gossamer Bio's higher probable upside, equities research analysts plainly believe Gossamer Bio is more favorable than Promis Neurosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gossamer Bio	2 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.22
Promis Neurosciences	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	2.88

Promis Neurosciences has lower revenue, but higher earnings than Gossamer Bio. Promis Neurosciences is trading at a lower price-to-earnings ratio than Gossamer Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gossamer Bio	$48.47M	0.85	-$170.37M	-$0.70	N/A
Promis Neurosciences	N/A	N/A	-$39.72M	-$8.54	N/A

Promis Neurosciences has a net margin of 0.00% compared to Gossamer Bio's net margin of -235.00%. Gossamer Bio's return on equity of 0.00% beat Promis Neurosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Gossamer Bio	-235.00%	N/A	-112.04%
Promis Neurosciences	N/A	-143.09%	-109.15%

Summary

Gossamer Bio beats Promis Neurosciences on 9 of the 15 factors compared between the two stocks.

How does Gossamer Bio compare to Cibus?

Cibus (NASDAQ:CBUS) and Gossamer Bio (NASDAQ:GOSS) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, profitability, earnings, valuation, dividends, institutional ownership and risk.

Gossamer Bio has a net margin of -235.00% compared to Cibus' net margin of -2,258.89%. Gossamer Bio's return on equity of 0.00% beat Cibus' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cibus	-2,258.89%	-287.03%	-27.99%
Gossamer Bio	-235.00%	N/A	-112.04%

Cibus has higher earnings, but lower revenue than Gossamer Bio. Cibus is trading at a lower price-to-earnings ratio than Gossamer Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cibus	$3.64M	33.18	-$127.08M	-$1.65	N/A
Gossamer Bio	$48.47M	0.85	-$170.37M	-$0.70	N/A

Cibus has a beta of 1.59, suggesting that its share price is 59% more volatile than the broader market. Comparatively, Gossamer Bio has a beta of 2, suggesting that its share price is 100% more volatile than the broader market.

Cibus currently has a consensus target price of $9.00, indicating a potential upside of 469.62%. Gossamer Bio has a consensus target price of $3.20, indicating a potential upside of 1,722.32%. Given Gossamer Bio's stronger consensus rating and higher probable upside, analysts plainly believe Gossamer Bio is more favorable than Cibus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cibus	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Gossamer Bio	2 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.22

In the previous week, Gossamer Bio had 10 more articles in the media than Cibus. MarketBeat recorded 10 mentions for Gossamer Bio and 0 mentions for Cibus. Gossamer Bio's average media sentiment score of 0.20 beat Cibus' score of 0.00 indicating that Gossamer Bio is being referred to more favorably in the news media.

Company	Overall Sentiment
Cibus	Neutral
Gossamer Bio	Neutral

33.8% of Cibus shares are held by institutional investors. Comparatively, 81.2% of Gossamer Bio shares are held by institutional investors. 29.9% of Cibus shares are held by insiders. Comparatively, 3.7% of Gossamer Bio shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Gossamer Bio beats Cibus on 12 of the 16 factors compared between the two stocks.

How does Gossamer Bio compare to TuHURA Biosciences?

Gossamer Bio (NASDAQ:GOSS) and TuHURA Biosciences (NASDAQ:HURA) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, media sentiment, risk, analyst recommendations, institutional ownership, profitability, valuation and earnings.

Gossamer Bio has a beta of 2, indicating that its share price is 100% more volatile than the broader market. Comparatively, TuHURA Biosciences has a beta of -0.02, indicating that its share price is 102% less volatile than the broader market.

In the previous week, Gossamer Bio had 7 more articles in the media than TuHURA Biosciences. MarketBeat recorded 10 mentions for Gossamer Bio and 3 mentions for TuHURA Biosciences. TuHURA Biosciences' average media sentiment score of 0.48 beat Gossamer Bio's score of 0.20 indicating that TuHURA Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Gossamer Bio	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
TuHURA Biosciences	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

81.2% of Gossamer Bio shares are held by institutional investors. Comparatively, 0.6% of TuHURA Biosciences shares are held by institutional investors. 3.7% of Gossamer Bio shares are held by insiders. Comparatively, 6.1% of TuHURA Biosciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

TuHURA Biosciences has a net margin of 0.00% compared to Gossamer Bio's net margin of -235.00%. Gossamer Bio's return on equity of 0.00% beat TuHURA Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Gossamer Bio	-235.00%	N/A	-112.04%
TuHURA Biosciences	N/A	-156.47%	-106.98%

TuHURA Biosciences has lower revenue, but higher earnings than Gossamer Bio. TuHURA Biosciences is trading at a lower price-to-earnings ratio than Gossamer Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gossamer Bio	$48.47M	0.85	-$170.37M	-$0.70	N/A
TuHURA Biosciences	N/A	N/A	-$30.05M	-$0.54	N/A

Gossamer Bio presently has a consensus price target of $3.20, indicating a potential upside of 1,722.32%. TuHURA Biosciences has a consensus price target of $9.00, indicating a potential upside of 328.57%. Given Gossamer Bio's higher probable upside, research analysts plainly believe Gossamer Bio is more favorable than TuHURA Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gossamer Bio	2 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.22
TuHURA Biosciences	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

Summary

TuHURA Biosciences beats Gossamer Bio on 8 of the 15 factors compared between the two stocks.

Get Gossamer Bio News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GOSS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

GOSS vs. The Competition

Export

Metric	Gossamer Bio	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$40.53M	$4.03B	$7.26B	$12.73B
Dividend Yield	N/A	3.60%	2.53%	8.86%
P/E Ratio	-0.25	12.66	273.28	25.38
Price / Sales	0.85	1,309.16	613.48	92.60
Price / Cash	N/A	106.87	77.82	52.26
Price / Book	-0.44	16.29	12.89	6.14
Net Income	-$170.37M	-$22.72M	$3.47B	$349.01M
7 Day Performance	3.23%	0.34%	0.61%	-0.27%
1 Month Performance	-3.25%	8.52%	5.73%	0.68%
1 Year Performance	-93.00%	52.66%	25.37%	14.84%

Gossamer Bio Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
GOSS Gossamer Bio	2.566 of 5 stars	$0.18 +1.7%	$3.20 +1,722.3%	-93.2%	$40.53M	$48.47M	N/A	180
TLSA Tiziana Life Sciences	1.2388 of 5 stars	$1.15 +0.9%	N/A	-44.3%	$145.07M	N/A	N/A	8	News Coverage Analyst Forecast Gap Up
IMDX Oncocyte	1.7276 of 5 stars	$4.32 -0.5%	$10.50 +143.1%	N/A	$142.02M	$4.05M	N/A	120
PMN Promis Neurosciences	2.8883 of 5 stars	$14.80 +2.0%	$34.00 +129.7%	+12.2%	$130.12M	N/A	N/A	5
CBUS Cibus	1.8238 of 5 stars	$1.73 +1.8%	$9.00 +420.2%	+23.4%	$129.93M	$3.64M	N/A	48

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:GOSS) was last updated on 9/4/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Gossamer Bio (GOSS) Competitors

GOSS vs. TLSA, IMDX, PMN, CBUS, and HURA

How does Gossamer Bio compare to Tiziana Life Sciences?

Summary

How does Gossamer Bio compare to Oncocyte?

Summary

How does Gossamer Bio compare to Promis Neurosciences?

Summary

How does Gossamer Bio compare to Cibus?

Summary

How does Gossamer Bio compare to TuHURA Biosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GOSS vs. The Competition

Gossamer Bio Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Gossamer Bio (GOSS) Competitors

GOSS vs. TLSA, IMDX, PMN, CBUS, and HURA

How does Gossamer Bio compare to Tiziana Life Sciences?

Is GOSS or TLSA more profitable?

Do analysts recommend GOSS or TLSA?

Which has preferable earnings and valuation, GOSS or TLSA?

Does the media refer more to GOSS or TLSA?

Which has more risk & volatility, GOSS or TLSA?

Do insiders & institutionals have more ownership in GOSS or TLSA?

Summary

How does Gossamer Bio compare to Oncocyte?

Which has preferable valuation & earnings, GOSS or IMDX?

Which has more risk & volatility, GOSS or IMDX?

Do analysts rate GOSS or IMDX?

Is GOSS or IMDX more profitable?

Do insiders and institutionals have more ownership in GOSS or IMDX?

Does the media favor GOSS or IMDX?

Summary

How does Gossamer Bio compare to Promis Neurosciences?

Which has more volatility and risk, GOSS or PMN?

Does the media favor GOSS or PMN?

Do institutionals & insiders have more ownership in GOSS or PMN?

Do analysts prefer GOSS or PMN?

Which has preferable valuation and earnings, GOSS or PMN?

Is GOSS or PMN more profitable?

Summary

How does Gossamer Bio compare to Cibus?

Is CBUS or GOSS more profitable?

Which has stronger earnings & valuation, CBUS or GOSS?

Which has more risk and volatility, CBUS or GOSS?

Do analysts recommend CBUS or GOSS?

Does the media refer more to CBUS or GOSS?

Do institutionals and insiders believe in CBUS or GOSS?

Summary

How does Gossamer Bio compare to TuHURA Biosciences?

Which has more volatility & risk, GOSS or HURA?

Does the media prefer GOSS or HURA?

Do institutionals and insiders have more ownership in GOSS or HURA?

Is GOSS or HURA more profitable?

Which has stronger earnings & valuation, GOSS or HURA?

Do analysts prefer GOSS or HURA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GOSS vs. The Competition

Gossamer Bio Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools